Patent · US Active

Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist

US10023649B2 · kind B2 · utility

0Cited by

5References

24Claims

0Family size

Assignees

PFIZER INC. · US
KYOWA HAKKO KIRIN CO., LTD. · JP

Inventors

Chia-Yang Lin · Palo Alto, US
Shihao Chen · Foster City, US
LiFen Lee · Palo Alto, US
Shobha Potluri · South San Francisco, US
Denis Healy · Chicago, US
Margaret Ann Marshall · Princeton, US
Naoki Sawada · Tokyo, JP

Key dates

Filing date	May 15, 2015
Grant date	Jul 17, 2018
Priority date	—
Expiry date	May 15, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.